Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations
Condition(s):Metastatic Castration-resistant Prostate CancerLast Updated:November 14, 2022Completed
Hide Studies Not Open or Pending
Condition(s):Metastatic Castration-resistant Prostate CancerLast Updated:November 14, 2022Completed
Condition(s):Metastatic MelanomaLast Updated:June 9, 2022Completed
Condition(s):Advanced Metastatic Cancer; Advanced Prostate CancerLast Updated:February 7, 2024Completed
Condition(s):Metastatic Pancreatic AdenocarcinomaLast Updated:December 23, 2022Completed
Condition(s):MelanomaLast Updated:December 23, 2022Completed
Condition(s):CD19 Positive; CD20 Positive; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma; Refractory Small Lymphocytic LymphomaLast Updated:October 6, 2023Recruiting
Condition(s):Multiple Myeloma; Melanoma; Synovial Sarcoma; Myxoid/Round Cell LiposarcomaLast Updated:June 22, 2023Terminated
Condition(s):Advanced SarcomaLast Updated:September 25, 2023Recruiting
Condition(s):Diffuse Midline Glioma, H3 K27M-MutantLast Updated:January 17, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.